New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it has advanced the market access strategies for its innovative plant-based drugs Botreso and PCP, after an analysis of their clinical efficacy and competitive advantages. As previously announced, its first core product, Botreso, ...